EUCTR2005-003482-17-IE进行中（未招募）1 期
A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Eligible subjects will be considered for inclusion in this study if they meet all of the following criteria:
- •1) Males & females, 18 years of age or older.
- •2) Diagnosis of UC, as verified by colonoscopy or barium enema performed within 36 months prior to consent.
- •3) Severe active disease, as defined by Modified TrueLove & Witts (MTWSI) =11 at consent, with a confirmatory MTWSI =10 on or after the fifth consecutive day of IV steroids and within 1 day prior to randomization/registration.
- •4) Mayo score =10 and a Mayo mucosal subscore (finding of flexible proctosigmoidoscopy) of =2. The Mayo score will be calculated on the day of sigmoidoscopy by a blinded gastroenterologist, after a minimum of 3 consecutive days (i.e. on or after the fourth consecutive day) of IV steroids.
- •5) Agreement to use adequate contraception by male or female subjects of reproductive potential throughout the study and for 3 months after receiving the last dose of study drug.
- •6) Negative serum pregnancy test at screening in female subjects of childbearing potential.
- •7) Negative Clostridium difficile test within 10 days prior to the first dose of study drug.
- •8) Ability to understand the purpose and risks of the study and provide signed and dated informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects will be ineligible for this study if they meet any one of the following criteria:
- •1) UC requiring immediate surgical, endoscopic, or radiologic interventions, including massive hemorrhage, perforation and sepsis, suppurative complications (intra-abdominal or perianal abscesses), or toxic megacolon requiring imminent intervention.
- •2) History of total proctocolectomy, or subtotal colectomy with ileorectal anastomosis.
- •3) Presence of ileostomy.
- •4) White blood cell count less than 2.5 x 10 (E3)/mcL; platelet count less than 150 x 10 (E3)/mcL; or hemoglobin level less than 8g/dL.
- •5) Active medically significant infections, particularly those of viral etiology, e.g. known CMV colitis. This includes any incidence of medically significant opportunistic infections(*) within the past 12 months. (*) Medically significant opportunistic infections include, but are not limited to, Pneumocystis carinii pneumonia, disseminated CMV, toxoplasmosis, histoplasmosis, progressive multifocal leukoencephalopathy, tuberculosis, aspergillosis, cryptococcal meningitis.
- •6) Live vaccination within 6 weeks prior to randomization (Subjects may not receive a live vaccine during dosing or for 60 days after receiving the last dose of study drug).
- •7) History of deep vein thrombophlebitis or pulmonary embolus.
- •8) Significant organ dysfunction, inluding cardiac, renal, liver, CNS, pulmonary, vascular, gastrointestinal, endocrine, or laboratory abnormality (e.g. creatinine =1.6 mg/dL; ALT or AST = 1.5X the upper limit of normal [ULN]; alkaline phosphatase = 1.5X ULN); a history of myocardial infarction, coronary artery disease, congestive heart failure, or arrhythmias within 6 months prior to consent.
- •9) History of lymphoproliferative disorder (LPD) or malignancy other than nonmelanoma skin cancer or carcinoma in situ of the cervix that has been adequately treated.
- •10) Seropositive for infection with human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) surface antigen, or hepatitis C virus (HCV) antibody.
- •11) Infliximab-treated subjects may not receive study drug until 4 weeks after their first dose or 2 weeks after a subsequent dose of infliximab.
- •12) Treatment with cyclosporine or tacrolimus (FK506) within 2 weeks prior to randomization.
- •13) Treatment with any other investigational drug or therapy within 60 days prior to randomization.
- •14) Any condition that, in the investigator’s opinion, makes the subject unsuitable for study participation.
- •15) Initiation or increase of dosing of 6-mercaptopurine, azathioprine, or methotrexate within 60 days immediately prior to randomization.
- •16) Failure to discontinue any UC drug (including, but not limited to 6-mercaptopurine, azathioprine, or methotrexate), except glucocorticoids or 5-ASA, prior to randomization.
- •17) Pregnancy or nursing.
- •18) Nontherapeutic levels of chronic anti-seizure medications in subjects with a prior history of seizures, as tested within 4 days prior to randomization.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisIntravenous steroid-refractory ulcerative colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365EUCTR2005-003482-17-GBPDL BioPharma, Inc.165
进行中（未招募）
不适用
A Phase 2, Randomized, Double-blind, Multicenter, Dose-Exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative ColitisEstudio fase 2, aleatorizado, doble ciego, multicéntrico, de exploración de dosis de Visilizumab en sujetos con colitis ulcerosa refractaria a esteróides intravenosos.Intravenous steroid-refractory ulcerative colitis (IVSR-UC)MedDRA version: 8.0Level: LLTClassification code 10045265EUCTR2005-003482-17-ESPDL BioPharma, Inc.100
进行中（未招募）
不适用
A Phase 2, Randomized, Double-blind, Multicenter, Dose-exploration Study of Visilizumab in Subjects with Intravenous Steroid-Refractory Ulcerative Colitis - RESTORE™ DIntravenous steroid-refractory ulcerative colitis (IVSR-UC)MedDRA version: 9.0Level: LLTClassification code 10045365EUCTR2005-003482-17-GRPDL BioPharma, Inc.100
已完成
2 期
A Study of JNJ-73763989 + Nucleos(t)ide Analog in Participants Co-infected with Hepatitis B and Hepatitis D VirusJPRN-jRCT2071200049akama Takahiro190
进行中（未招募）
1 期
A Study of the Effectiveness and Safety of Ustekinumab (STELARA®) and CNTO 1959 Administered Under the Skin of Patients with Active Rheumatoid Arthritis, Despite Existing Methotrexate TherapyRheumatoid ArthritisEUCTR2011-001122-18-CZJanssen-Cilag International NV250